



ACCESS
Immunoassay Systems

Instructions For Use

© 2018 Beckman Coulter, Inc. All rights reserved.

Access AccuTnI+3
Troponin I

REF A98264

FOR PROFESSIONAL USE ONLY

For Use on UniCel DxI Systems† with Test name: TnIDx

ANNUAL REVIEW

Reviewed by	Date	Reviewed by	Date

PRINCIPLE

INTENDED USE

The Access AccuTnI+3 Reagent is a paramagnetic particle, chemiluminescent immunoassay for the highly sensitive quantitative determination of cardiac troponin I (cTnI) levels in human serum and plasma using the UniCel DxI Immunoassay System to aid in the diagnosis of myocardial infarction.

† UniCel DxI 600, UniCel DxI 800, UniCel DxC 880i, UniCel DxC 860i, UniCel DxC 680i, UniCel DxC 660i

SUMMARY AND EXPLANATION

The troponins (I, C, and T) are members of a complex of proteins that modulate the calcium-mediated interaction between actin and myosin within muscle cells.¹ The nomenclature of these distinct proteins of the troponin complex is derived from their respective function in muscle contraction. Troponin T anchors the troponin complex to tropomyosin of the thin filament, whereas troponin I inhibits actomyosin ATPase, and troponin C is a calcium-binding subunit. Three isoforms of troponin I (TnI) have been identified: one associated with fast-twitch skeletal muscle, one with slow-twitch skeletal muscle, and one with cardiac muscle. The slow and fast-twitch isoforms have a similar molecular weight of approximately 20,000 dalton (Da) each. The cardiac-specific TnI (cTnI) isoform has a molecular weight of approximately 24,000 Da and contains a post-translational tail of 31 amino acids on the N-terminus of the molecule.^{2,3} This sequence and the 42% and 45% dissimilarity with the sequences of the other two isoforms have made possible the generation of highly specific monoclonal antibodies without cross-reactivity with other non-cardiac TnI forms.^{4,5} As a result of its high tissue specificity cTnI is a cardio-specific, highly sensitive marker for myocardial damage. The Access AccuTnI+3 assay uses monoclonal antibodies specifically directed against human cardiac troponin I.

In myocardial infarction (MI), cTnI levels rise in the hours after the onset of cardiac symptoms, reaching a peak at 12-16 hours and can remain elevated for 4-9 days post MI.^{6,7} Numerous pathologies can potentially cause troponin elevations without overt ischemic heart disease.^{8,9} These pathologies include, but are not limited to, congestive heart failure, acute and chronic trauma, electrical cardioversion, hypertension, hypotension, arrhythmias, pulmonary embolism, severe asthma, sepsis, critical illness, myocarditis, stroke, non-cardiac surgery, extreme exercise, drug toxicity

(adriamycin, 5-fluorouracil, herceptin, snake venoms), end stage renal disease, and rhabdomyolysis with cardiac injury.^{9,10} Importantly, these other etiologies rarely demonstrate the classic rising and falling pattern experienced with a MI which highlights the importance of serial monitoring when the clinical scenario is confusing.^{8,11,12}

Definition of Myocardial Infarction

In 2012, a Task Force of the Joint European Society of Cardiology (ESC), American College of Cardiology Foundation (ACCF), American Heart Association (AHA), and World Heart Federation (WHF) published an updated redefinition of MI in which biomarkers play a central role.¹² Professional groups recognize cardiac troponin (cTn) as the preferred biomarker for MI diagnosis.

The 2012 Third Universal Definition of Myocardial Infarction document states that the following is one criterion for the diagnosis of MI:

- “Detection of a rise and/or fall of cardiac biomarkers values [preferably cardiac troponin (cTn)] with at least one value above the 99th percentile of the upper reference limit (URL) and with at least one of the following:
 - Symptoms of ischemia;
 - New or presumed new ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB);
 - Development of pathological Q waves in the ECG;
 - Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality;
 - Identification of an intracoronary thrombus by angiography or autopsy.”¹²

Additionally, the Third Universal Definition of Myocardial Infarction document recommends an optimal imprecision level (coefficient of variation, or CV) for troponin assays $\leq 10\%$ at the 99th percentile URL of a healthy population, and recognizes that assays with imprecision $> 10\%$ CV at the 99th percentile URL make determination of a significant change more difficult, but do not cause false positive results. However, assays with CV $> 20\%$ at the 99th percentile should not be used.¹²

Because cTn may not appear in blood within the first hours after myocardial injury,¹³ cTn should be measured upon admission, and then serially at regular intervals to demonstrate a rise and/or fall in cTn values. When an increased cTn value is encountered in the absence of myocardial ischemia, a careful search for other possible etiologies of cardiac damage should be undertaken.¹⁴

METHODOLOGY

The Access AccuTnI+3 assay is a two-site immunoenzymatic (“sandwich”) assay. Monoclonal anti-cTnI antibody conjugated to alkaline phosphatase is added to a reaction vessel along with a surfactant-containing buffer and sample. After a short incubation, paramagnetic particles coated with monoclonal anti-cTnI antibody are added. The human cTnI binds to the anti-cTnI antibody on the solid phase, while the anti-cTnI antibody - alkaline phosphatase conjugate reacts with different antigenic sites on the cTnI molecules.

After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then, the chemiluminescent substrate is added to the vessel and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of cTnI in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve.

SPECIMEN

SPECIMEN COLLECTION AND PREPARATION

1. Serum and lithium heparin plasma are preferred samples. Serum and plasma (heparin and EDTA) are acceptable samples. **Heparin and EDTA plasma and serum samples should not be used interchangeably.**¹⁵ Each laboratory should determine the acceptability of its own blood collection tubes and serum separation products. Variations in these products may exist between manufacturers and, at times, from lot-to-lot. The AMI cutoff value presented in the Clinical Performance section applies to heparin plasma and serum samples. A conversion factor of 0.86 should be applied to the AMI cutoff for EDTA plasma samples.

EXAMPLE: 0.86 x [lithium heparin plasma AMI cutoff] = [EDTA plasma AMI cutoff].

2. The role of preanalytical factors in laboratory testing has been described in a variety of published literature.^{16,17,18} To minimize the effect of preanalytical factors, observe the following recommendations for handling, processing, and storing blood samples:
 - Collect all blood samples observing routine precautions for venipuncture.¹⁶
 - Allow serum samples to clot completely before centrifugation. Time to clot may be prolonged in serum samples due to the patient's clinical condition or in patients receiving anticoagulant therapy.¹⁶
 - Keep tubes stoppered at all times.¹⁶
 - Store samples tightly stoppered at room temperature (15 to 30°C) for no longer than two hours.
 - Samples should be centrifuged, physically separated from contact with cells, and refrigerated as soon as possible.
 - Remove any residual fibrin or cellular matter. Failure to do so can contribute to falsely elevated results.
 - For plasma, avoid transferring material from the white blood cell/platelet layer located just above the red blood cells. If a fixed angle rotor is used for centrifugation, care should be taken to avoid resuspending platelets.
 - Turbid serum or plasma samples containing particulate matter should be transferred from the original tube and recentrifuged prior to assay. A specimen (original tube) that contains a separating device (gel barrier) is never to be recentrifuged.
 - If the assay will not be completed within 24 hours, or for shipment of samples, freeze at -20°C or colder.¹⁶
 - Follow blood collection tube manufacturer's recommendations for centrifugation.
 - Samples may be stored for six months at -20°C.
3. Each laboratory should determine the acceptability of its own blood collection tubes and serum separation products. Variations in these products may exist between manufacturers and, at times, from lot-to-lot.
4. Thaw samples only once and centrifuge all thawed samples prior to analysis. Do not thaw in a water bath.

REAGENTS

PRODUCT INFORMATION

Access AccuTnl+3 Reagent Pack (for use on UniCel Dxl Immunoassay Systems)

Cat. No. A98264: 100 determinations, 2 packs, 50 tests/pack

- Provided ready to use.
- Store upright and refrigerate at 2 to 10°C.
- Refrigerate at 2 to 10°C for a minimum of two hours before use on the instrument.
- Stable until the expiration date stated on the label when stored at 2 to 10°C.
- Stable at 2 to 10°C for 56 days after initial use.
- Signs of possible deterioration are a broken elastomeric layer on the pack or control values out of range.
- If the reagent pack is damaged (i.e., broken elastomer), discard the pack.

R1a:	Paramagnetic particles coated with mouse monoclonal anti-human cardiac troponin I (cTnl) suspended in TRIS buffered saline, with surfactant, bovine serum albumin (BSA) matrix, < 0.1% sodium azide, and 0.1% ProClin* 300.
R1b:	0.1 N NaOH.


R1c:	TRIS buffered saline, surfactant, < 0.1% sodium azide, and 0.1% ProClin 300.
R1d:	Mouse monoclonal anti-human cTnI alkaline phosphatase conjugate diluted in ACES buffered saline, with surfactant, BSA matrix, protein (bovine, goat, mouse), < 0.1% sodium azide, and 0.25% ProClin 300.

*ProClin™ is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.

WARNING AND PRECAUTIONS

- For *in vitro* diagnostic use.
- Patient samples and blood-derived products may be routinely processed with minimum risk using the procedure described. However, handle these products as potentially infectious according to universal precautions and good clinical laboratory practices, regardless of their origin, treatment, or prior certification. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers in accordance with local regulations and guidelines.
- For hazards presented by the product refer to the following sections: REACTIVE INGREDIENTS, GHS HAZARD CLASSIFICATION and EU HAZARD CLASSIFICATION.

REACTIVE INGREDIENTS



CAUTION

Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations.

GHS HAZARD CLASSIFICATION

Paramagnetic Particles
(Compartment R1a)

WARNING



H316	Causes mild skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
P280	Wear protective gloves, protective clothing and eye/face protection.
P332+P313	If skin irritation occurs: Get medical advice/attention.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P337+P313	If eye irritation persists: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before use.
	Ethoxylated lauryl alcohol 1 - <3%

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

0.1N NaOH (Compartment R1b)

DANGER



H314

Causes severe skin burns and eye damage.

P280

Wear protective gloves, protective clothing and eye/face protection.

P301+P330+P331

IF SWALLOWED: rinse mouth. Do NOT induce vomiting.

P303+P361+P353

IF ON SKIN (or hair): Rinse skin with water.

P305+P351+P338

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P310

Immediately call a POISON CENTER or doctor/physician.

Sodium Hydroxide 0.1 - 1%

Ancillary Reagent (Compartment R1c)

WARNING



H316

Causes mild skin irritation.

H317

May cause an allergic skin reaction.

P280

Wear protective gloves, protective clothing and eye/face protection.

P332+P313

If skin irritation occurs: Get medical advice/attention.

P333+P313

If skin irritation or rash occurs: Get medical advice/attention.

P362+P364

Take off contaminated clothing and wash it before use.

3-((3-Cholamidopropyl)dimethylammonio)-propanesulfonate 1 - 5%

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Conjugate (Compartment R1d)

WARNING



H316

Causes mild skin irritation.

H317

May cause an allergic skin reaction.

P280	Wear protective gloves, protective clothing and eye/face protection.
P332+P313	If skin irritation occurs: Get medical advice/attention.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before use.

Lithium Chloride 1 - 5%
reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

SDS	Safety Data Sheet is available at techdocs.beckmancoulter.com
-----	--

EUROPEAN HAZARD CLASSIFICATION

Paramagnetic Particles (Compartment R1a)	Xi;R43	
	R43	May cause sensitization by skin contact.
	S28	After contact with skin, wash immediately with plenty of soap and water.
0.1N NaOH (Compartment R1b)	S37	Wear suitable gloves.
	C;R34	
	R34	Causes burns.
	S25	Avoid contact with eyes.
	S26	In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
	S28	After contact with skin, wash immediately with plenty of soap and water.
Ancillary Reagent (Compartment R1c)	S36/37/39	Wear suitable protective clothing, gloves and eye/face protection.
	S45	In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
	Xi;R43	
	R43	May cause sensitization by skin contact.
	S28	After contact with skin, wash immediately with plenty of soap and water.
Conjugate (Compartment R1d)	S37	Wear suitable gloves.
	Xi;R43	
	R43	May cause sensitization by skin contact.
	S28	After contact with skin, wash immediately with plenty of soap and water.
	S37	Wear suitable gloves.

MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT

1. Access AccuTnl+3 Calibrators (for use on UniCel Dxl Immunoassay Systems)
Provided at zero and approximately 0.2, 0.9, 3.7, 20, and 80 ng/mL (µg/L).
Cat. No. A98265
2. Quality Control (QC) materials: commercial control material.
3. Access Substrate
Cat. No. 81906
4. UniCel Dxl Wash Buffer II,
Cat. No. A16793

EQUIPMENT AND MATERIALS

R1 Access AccuTnl+3 Reagent Packs

CALIBRATION

CALIBRATION INFORMATION

Run the Access AccuTnl+3 Calibrator S0 and S1 in quadruplicate, and the Calibrator S2-S5 in duplicate.

An active calibration curve is required for all tests. For the Access AccuTnl+3 assay, calibration is required every 56 days. Refer to the appropriate system manuals and/or Help system for information on calibration theory, configuring calibrators, calibrator test request entry, and reviewing calibration data.

QUALITY CONTROL

Quality control materials simulate the characteristics of patient samples and are essential for monitoring the system performance of immunochemical assays. Because samples can be processed at any time in a “random access” format rather than a “batch” format, quality control materials should be included in each 24-hour time period.¹⁹ Include quality control materials that cover at least two levels of analyte. It is recommended that at least one level is targeted near the MI cutoff. Several options are commercially available that meet these criteria. More frequent use of controls or the use of additional controls is left to the discretion of the user based on good laboratory practices or laboratory accreditation requirements and applicable laws. Follow manufacturer's instructions for reconstitution and storage. Each laboratory should establish mean values and acceptable ranges to assure proper performance of the quality control material. The thermal profile of native human cardiac troponin I was used in development of the assay. Quality control materials containing troponin I not from this source (e.g. recombinant antigens) may behave differently. Quality control results that do not fall within acceptable ranges may indicate invalid test results. Examine all test results generated since obtaining the last acceptable quality control test point for this analyte. Refer to the appropriate system manuals and/or Help system for information about reviewing quality control results.

TESTING PROCEDURE(S)

PROCEDURAL COMMENTS

1. Refer to the appropriate system manuals and/or Help system for a specific description of installation, start-up, principles of operation, system performance characteristics, operating instructions, calibration procedures, operational limitations and precautions, hazards, maintenance, and troubleshooting.
2. Mix contents of new (unpunctured) reagent packs by gently inverting pack several times before loading on the instrument. Do not invert open (punctured) packs.
3. Use fifty-five (55) μL of sample for each determination in addition to the sample container and system dead volumes. Refer to the appropriate system manuals and/or Help system for the minimum sample volume required.
4. The system default unit of measure for sample results is ng/mL. To change sample reporting units to the International System of Units (SI units) $\mu\text{g/L}$, or alternate units such as pg/mL or ng/L, refer to the appropriate system manuals and/or Help system. To manually convert concentrations to the International System ($\mu\text{g/L}$), multiply ng/mL by multiplication factor 1. For manual conversion to pg/mL or ng/L, multiply ng/mL by a factor of 1,000.

PROCEDURE

Refer to the appropriate system manuals and/or Help system for information on managing samples, configuring tests, requesting tests, and reviewing test results.

RESULTS INTERPRETATION

Patient test results are determined automatically by the system software. The amount of analyte in the sample is determined from the measured light production by means of the stored calibration data, and the application of

mathematical adjustments. Patient test results can be reviewed using the appropriate screen. Refer to the appropriate system manuals and/or Help system for complete instructions on reviewing sample results.

REPORTING RESULTS

EXPECTED RESULTS

Beckman Coulter conducted two different studies to establish the 99th percentile upper reference limit (URL) of different adult populations. Two studies were carried out to address variability of URL values that may be due to study-to-study differences in subject inclusion and exclusion criteria. Both populations were considered to be cardiac healthy. Individual laboratories should confirm the URLs described in this section, to assure proper representation of specific populations and sample types and to reflect current practice at their institutions.

Adult European Population, Targeted Age Range of > 40

Beckman Coulter conducted a study to establish the 99th percentile URL in a population of adults with no known cardiovascular disease. Serum samples were selected from residual specimens obtained during office visits at general practice institutions in the area in and surrounding London, United Kingdom. De-identified samples were obtained from approximately 1,000 subjects, > 40 years of age with approximately equal numbers of males and females. The race and ethnicity of study subjects were consistent with that of the local population (Asian, Caucasian and Afro-Caribbean).

Surrogate testing to confirm cardiac health was performed prior to inclusion in the study cohort. Subjects were excluded from the study if any of the following tests were abnormal:

- Urea and Electrolytes
- Liver Function Tests
- Glucose
- NT-proBNP

Results from this study demonstrated the 99th percentile URL to be 0.04 ng/mL (95% CI: 0.03-0.08).

Table 1.0 99th Percentile URL of a European Population

n	Age Range (years)	99 th Percentile (95% CI)
998	40 - 99	0.04 ng/mL (0.03 - 0.08)

Apparently Healthy Adult US Population, Extended Age Range of ≥ 18, Approximately 40% Below 40

Beckman Coulter conducted a multicenter prospective study to establish the 99th percentile upper reference limit (URL) in a population of apparently healthy adults with no known diseases of the cardiovascular system or other serious acute or chronic diseases or infections. Lithium heparin plasma samples were evaluated. Five hundred twenty-seven (527) subjects were enrolled at seven geographically diverse locations. Both male and female subjects were included with approximately 60% above the age of 40 years.

Subjects were excluded from the study if they met any of the following criteria:

- Disease(s) of/ or affecting the cardiovascular system, including: hypertension, angina, coronary artery disease, history of MI, history of percutaneous transcatheter angiography/angioplasty (PTCA) or coronary artery bypass graft (CABG), peripheral artery disease including cerebrovascular disease/stroke or deep vein thrombosis, hemostatic disorders, and/or congestive heart failure.
- Currently taking a medication for cardiovascular disease, including: ACE inhibitors, angiotensin II receptor blockers, beta-blockers, calcium channel blockers, diuretics, blood thinners, and/or platelet inhibitors.
- Diabetes.
- Chronic kidney disease.

- Other serious chronic disease(s), including: cancer, leukemia, emphysema, chronic obstructive pulmonary disease (COPD), HIV, HBV, HCV, lupus erythematosus, rheumatoid arthritis, and/or scleroderma.
- Acute bacterial or viral infection, including: bronchitis, upper respiratory infection, strep throat, influenza, pneumonia, mononucleosis, oral/genital herpes outbreak, and/or urinary tract infection.
- Pregnancy.

Results from this study demonstrated the 99th percentile URL to be 0.02 ng/mL (95% CI: 0.01-0.04).

Table 2.0 99th Percentile URL of a Healthy US Population

n	Age Range (years)	99 th Percentile (95% CI)
527	18-94	0.02 ng/mL (0.01-0.04)

CLINICAL PERFORMANCE EVALUATION

Diagnosis of Myocardial Infarction

As described in the Summary and Explanation section of this document, the Universal Definition of Myocardial Infarction document has recommended the use of more sensitive cTn assays and lower cutoffs. To establish clinical performance of Access AccuTnI+3 to aid in the diagnosis of MI, a clinical study was conducted to evaluate sensitivity (% MI correctly identified) and specificity (% non-MI correctly identified) at cutoffs near and at the 99th percentile URL.

The multicenter prospective study enrolled 1,929 subjects from Emergency Department (ED) patients presenting with chest pain or equivalent ischemic symptoms suggestive of Acute Coronary Syndromes (ACS). A total of 14 geographically diverse, primary care hospital-associated emergency departments participated, reflecting regional, urban, suburban, and rural patient populations.

Study endpoints (final diagnoses) were adjudicated by an independent panel of expert physicians using criteria consistent with the 2007 Universal Definition of Myocardial Infarction.^{11†} Investigators and adjudicators were blinded to the Access AccuTnI+3 assay results. All results presented below were based on the adjudicated diagnoses. The MI incidence was 13% (253/1929).

To assess performance of the Access AccuTnI+3 assay, study samples were tested at four independent testing facilities on UniCel Dxl Immunoassay System. Testing was performed using lithium heparin plasma samples.

† The 2012 Third Universal Definition of Myocardial Infarction was published after completion of this prospective study.¹²

Clinical Sensitivity and Specificity

The American College of Emergency Physicians (ACEP) recommends serial troponin measurements for patients presenting early after symptom onset (< 8 hours).²⁰ However, patient estimates of symptom timing may not be totally reliable, prompting serial sampling recommendations after admission to the emergency department. Based on these guidelines and literature recommendations, study results are presented for the following time intervals:

- < 8 hours and ≥ 8 hours after symptom onset
- Baseline, ≥ 1 - 3 hours, ≥ 3 - 6 hours, and ≥ 6 - 9 hours after admission

Receiver Operating Characteristic (ROC) curves and Areas Under the Curve (AUC) were generated for serial time intervals after symptom onset and admission. Study results showed the AccuTnI+3 assay to have significant diagnostic efficacy at all time intervals (AUCs 0.93-0.97, p < 0.0001).

Diagnostic sensitivity (% MI correctly diagnosed) and specificity (% Non-MI correctly diagnosed) were also determined as shown in the tables below. Estimates of sensitivity and specificity were determined by dividing the number of patients correctly diagnosed by the AccuTnI+3 assay (n) by the total number of patients with an adjudicated diagnosis (N). Cutoffs of 0.02 ng/mL, 0.03 ng/mL, and 0.04 ng/mL yielded 96%, 92%, and 86% sensitivity respectively for cTnI measurements ≥ 8 hours after symptom onset. Specificity ranged from 83% to 93%.

A cutoff of 0.02 ng/mL or 0.03 ng/mL may be used as an aid in the diagnosis of MI. The Access AccuTnl+3 Limit of Quantitation (LoQ) is 0.04 ng/mL ($\mu\text{g/L}$) at 10% CV.

Table 3.0 Diagnostic Sensitivity and Specificity for Serial Time Intervals After Symptom Onset

Tnl cutoff for Diagnosis of MI (\geq) (ng/mL)	Hours After Symptom Onset	Sensitivity (MI patients correctly diagnosed)			Specificity (Non-MI patients correctly diagnosed)		
		%	n/N	95% CI	%	n/N	95% CI
0.02	< 8 hours	95	157/165	91 - 98	86	852/993	84 - 88
	\geq 8 hours	96	152/158	92 - 99	83	927/1,112	81 - 86
0.03	< 8 hours	90	148/165	84 - 94	91	902/993	89 - 93
	\geq 8 hours	92	145/158	86 - 96	89	993/1,112	87 - 91
0.04	< 8 hours	84	138/165	77 - 89	94	937/993	93 - 96
	\geq 8 hours	86	136/158	80 - 91	93	1,038/1,112	92 - 95

Table 4.0 Diagnostic Sensitivity and Specificity for Serial Time Intervals After Admission to the Emergency Department

Tnl cutoff for Diagnosis of MI (\geq) (ng/mL)	Hours After Admission to ED	Sensitivity (MI patients correctly diagnosed)			Specificity (Non-MI patients correctly diagnosed)		
		%	n/N	95% CI	%	n/N	95% CI
0.02	Baseline	91	230/253	87 - 94	85	1,422/1,675	83 - 87
	\geq 1 - 3	97	120/124	92 - 99	88	889/1,014	86 - 90
	\geq 3 - 6	98	153/157	94 - 99	83	779/941	80 - 85
	\geq 6 - 9	93	40/43	81 - 99	80	197/246	75 - 85
0.03	Baseline	84	213/253	79 - 89	90	1,508/1,675	89 - 91
	\geq 1 - 3	94	116/124	88 - 97	91	923/1,014	89 - 93
	\geq 3 - 6	91	143/157	86 - 95	89	839/941	87 - 91
	\geq 6 - 9	93	40/43	90 - 99	90	222/246	86 - 94
0.04	Baseline	72	182/253	66 - 77	94	1,577/1,675	93 - 95
	\geq 1 - 3	89	110/124	82 - 94	95	960/1,014	93 - 96
	\geq 3 - 6	83	131/157	77 - 89	93	875/941	91 - 95
	\geq 6 - 9	93	40/43	81 - 99	94	231/246	90 - 97

In clinical practice, even higher specificity is attained from detection of a rise and/or fall in cardiac biomarker values as described in the Universal Definition of Myocardial Infarction.^{11,12} When serial samples are obtained and the marker is considered in the clinical context of each patient, acute events such as MI may be distinguished from other conditions causing myocardial injury. The AccuTnl+3 assay is not intended to be used in isolation; results should be interpreted in conjunction with other diagnostic tests and clinical information.

Positive Predictive Value (PPV) and Negative Predictive Value (NPV)

Positive Predictive Values (PPV, probability of MI diagnosis in patients with elevated cTnl) and Negative Predictive Values (NPV, probability of non-MI diagnosis in patients with non-elevated cTnl) were calculated for the multicenter prospective study, per CLSI Guideline I/LA21-A2.²¹ Predictive value analysis, unlike ROC analysis, is directly proportional to the prevalence of disease in the intended use population. The overall MI prevalence of 13% in this study is consistent with literature and public health findings, and indicates that the study population is representative of the

intended use population. Non-representative study populations with high MI prevalence (35-50%) may overestimate apparent diagnostic accuracy, particularly PPVs (up to 80-90%).²² Since predictive value analysis is prevalence dependent, results will vary by region and facility.

Study results are shown in the following tables. Estimates of PPV were determined by dividing the number of patients with elevated cTnI values and adjudicated MI diagnoses (n) by the total number of patients with elevated cTnI values (N). Estimates of NPV were determined by dividing the number of patients with non-elevated cTnI values and adjudicated non-MI diagnoses (n) by the total number of patients with non-elevated cTnI values (N). NPVs indicate nearly all patients with cTnI values < 0.02 or 0.03 ng/mL were diagnosed with conditions other than myocardial infarction (non-MI). PPVs indicate that approximately 45-63% of patients with cTnI values ≥ 0.02 or 0.03 ng/mL were diagnosed with MI. The Access AccuTnI+3 Limit of Quantitation (LoQ) is 0.04 ng/mL (µg/L) at 10% CV. NPVs indicate that 96-99% of patients with cTnI values < 0.04 ng/mL were diagnosed with conditions other than myocardial infarction (non-MI). PPVs indicate that approximately 65-73% of patients with cTnI values ≥ 0.04 ng/mL were diagnosed with MI.

Table 5.0 PPV and NPV for Serial Time Intervals After Symptom Onset

AccuTnI cutoff (ng/mL)	Hours After Symptom Onset	Positive Predictive Value (Patients above cutoff diagnosed as MI)			Negative Predictive Value (Patients below cutoff diagnosed as Non-MI)		
		%	n/N	95% CI	%	n/N	95% CI
0.02	< 8 hours	53	157/298	47 - 59	99	852/860	98 - 100
	≥ 8 hours	45	152/337	40 - 51	99	927/933	99 - 100
0.03	< 8 hours	62	148/239	55 - 68	98	902/919	97 - 99
	≥ 8 hours	55	145/264	49 - 61	99	993/1,006	98 - 99
0.04	< 8 hours	71	138/194	64 - 77	97	937/964	96 - 98
	≥ 8 hours	65	136/210	58 - 71	98	1,038/1,060	97 - 99

Table 6.0 PPV and NPV for Serial Time Intervals After Admission to the Emergency Department

AccuTnI cutoff (ng/mL)	Hours After Admission to ED	Positive Predictive Value (Patients above cutoff diagnosed as MI)			Negative Predictive Value (Patients below cutoff diagnosed as Non-MI)		
		%	n/N	95% CI	%	n/N	95% CI
0.02	Baseline	48	230/483	43 - 52	98	1,422/1,445	98 - 99
	≥ 1 to 3	49	120/245	43 - 55	100	889/893	99 - 100
	≥ 3 to 6	49	153/315	43 - 54	100	779/783	99 - 100
	≥ 6 to 9	45	40/89	34 - 56	99	197/200	96 - 100
0.03	Baseline	56	213/380	51 - 61	97	1,508/1,548	97 - 98
	≥ 1 to 3	56	116/207	49 - 63	99	923/931	98 - 100
	≥ 3 to 6	58	143/245	52 - 65	98	839/853	97 - 99
	≥ 6 to 9	63	40/64	50 - 74	99	222/225	96 - 100
0.04	Baseline	65	182/280	59 - 71	96	1,577/1,648	95 - 97
	≥ 1 to 3	67	110/164	59 - 74	99	960/974	98 - 99
	≥ 3 to 6	67	131/197	59 - 73	97	875/901	96 - 98
	≥ 6 to 9	73	40/55	59 - 84	99	231/234	96 - 100

Note: Since predictive value analysis is prevalence-dependent, results will vary by region and facility.

These results are representative of the use of low troponin cutoffs, emphasizing the importance of serial samples when low cutoffs are used. However, even a single elevated troponin value (≥ 0.03 ng/mL) increased the probability of MI from 13% to 55-63%, providing important information to the clinician.

Non-MI patients with elevated cTnI values (Myocardial Injury)

Of the 1676 non-MI patients in the Beckman Coulter prospective multicenter pivotal trial, 188 (11%) had at least one cTnI value ≥ 0.03 ng/mL on one or more of the serial draws. Of these 188 patients, 98.4% (185/188) were found to have cardiac conditions such as angina, atrial fibrillation, cardiomyopathy, carditis, heart failure, severe coronary artery disease, tachycardia; or non-cardiac conditions such as renal failure or pulmonary embolism that may result in myocardial damage. Results are consistent with literature findings that cTnI may be elevated in non-MI patients with coronary and/or non-coronary disease with myocardial injury.^{23,24} Elevated cTnI values in a non-MI patient should not be disregarded. Troponin is specific for myocardial injury; serial samples and clinical context allow identification of patients with acute and chronic conditions causing myocardial injury.

PROCEDURAL NOTES

LIMITATIONS

1. This product is for use on UniCel DxI Immunoassay systems only. It is not compatible with Access 2 systems.
2. Ambient laboratory temperature should be maintained between 18°C and 28°C (64.4°F and 82.4°F) while conducting patient sample testing. This assay employs an algorithm to correct for laboratory temperature fluctuations that could impact the accuracy of troponin test results. Up to 10% residual systematic bias may be observed when comparing patient results obtained at 18°C and 28°C (64.4°F and 82.4°F).
3. Samples can be accurately measured within the analytical range of the assay (approximately 0.01-80 ng/mL [$\mu\text{g/L}$]). Do not dilute patient samples. Dependent upon the concentration of Troponin I in the sample (X), report results per the description in the table below, adapted from CLSI EP17-A2:²⁵

AccuTnI+3 Result (X) on DxI	Report result (X) as:
$X < 0.01$ ng/mL (LoD)	Troponin I not detected; result < 0.01 ng/mL
0.01 ng/mL (LoD) $\leq X < 0.02$ ng/mL (20% LoQ)	X ng/mL, interpret result with caution due to higher assay imprecision
$X \geq 0.02$ ng/mL (20% LoQ)	X ng/mL
$X > \sim 80$ ng/mL (S5 calibrator value)	$> \sim 80$ ng/mL

4. For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Additionally, other heterophile antibodies such as human anti-goat antibodies may be present in patient samples.^{26,27} Such interfering antibodies may cause erroneous results. Carefully evaluate the results of patients suspected of having these antibodies.
5. Other potential interferences in the patient sample could be present and may cause erroneous results in immunoassays. Some examples that have been documented in literature include rheumatoid factor, endogenous alkaline phosphatase, fibrin, and proteins capable of binding to alkaline phosphatase.^{28,29} Fibrinolytic agents activate proteases that may influence protein measurements, including troponin.³⁰ Carefully evaluate the results of patients suspected of having these types of interferences.
6. The thermal profile of native human cardiac troponin I was used in development of this assay. Troponin I not from this source (e.g. recombinant antigens) may behave differently.
7. The role of preanalytical factors in laboratory testing has been described in a variety of published literature.^{16,17,18} Following blood collection tube manufacturers' specimen collection and handling recommendations are essential to reduce preanalytical errors.

8. The Access AccuTnI+3 assay is not intended to be used in isolation. Results should be interpreted in conjunction with other diagnostic tests and clinical information. When serial samples are obtained and troponin is considered in the clinical context of each patient, acute events such as MI may be distinguished from other conditions causing myocardial injury.¹²
9. The Access AccuTnI+3 assay does not demonstrate any “hook” effect up to 2,000 ng/mL (µg/L).

PERFORMANCE CHARACTERISTICS

PERFORMANCE CHARACTERISTICS

SPECIFIC PERFORMANCE CHARACTERISTICS

LINEARITY

Representative data for linearity are provided for illustration only. Performance obtained in individual laboratories may vary.

The Access AccuTnI+3 assay demonstrates clinically acceptable linearity throughout the analytical measuring range. Twelve studies, based on CLSI EP6-A,³¹ were performed to determine linearity of the Access AccuTnI+3 assay. For each study, one high sample at or above the highest calibrator level and one low sample approximately at the limit of detection were mixed to make seven evenly distributed sample concentrations. Four replicates of the seven mixed samples, eight replicates of the low sample and eight replicates of the high sample were run on the UniCel DxI system. The Access AccuTnI+3 assay demonstrates linearity with a maximum deviation between a linear and non-linear fit of ≤ 15%.

IMPRECISION

Representative data for imprecision are provided for illustration only. Performance obtained in individual laboratories may vary.

This assay exhibits total imprecision of ≤ 8% at concentrations > 0.075 ng/mL (µg/L), and total Standard Deviation (SD) ≤ 0.006 ng/mL (µg/L) at concentrations ≤ 0.075 ng/mL (µg/L). One study, based on CLSI EP5-A2³² guidelines, provided the following data. This study used one low spiked patient pool, three commercial controls and one high patient pool. These samples were tested in duplicate in two runs per shift, two shifts per day, over a total of 11 days, generating at least 20 independent assays.

Sample	Mean (ng/mL)	Within Run (%CV)	Between Run (%CV)	Total Imprecision (%CV)
Low Spiked Patient Pool	0.05	5	7	8
Commercial Control 1	0.95	2	4	4
Commercial Control 2	3.19	2	6	6
Commercial Control 3	13.83	4	3	5
High Patient Pool	58.04	4	4	5

A separate study was performed to assess overall imprecision by incorporating additional variables than the study above. This overall imprecision study was conducted over 12 days, and included multiple UniCel DxI Immunoassay Systems, calibrations, reagent lots, and fluctuations in laboratory temperature. Three patient pools were analyzed throughout this study.

Sample	Mean (ng/mL)	Overall Imprecision (SD, ng/mL)	Overall Imprecision (%CV)
Patient pool 1	0.04	0.005	12
Patient pool 2	0.42	0.029	7
Patient pool 3	0.98	0.067	7

ANALYTICAL SPECIFICITY / INTERFERENCES

Representative data for analytical specificity/interferences are provided for illustration only. Performance obtained in individual laboratories may vary.

The following potential interfering substances were added to lithium heparin plasma pools at three concentrations of cTnI (approximately 0.01 ng/mL, 0.05 ng/mL, and 0.50 ng/mL). Additionally, each substance was tested at two concentrations and run on a UniCel DxI Immunoassay System. Values were calculated as described in CLSI EP7-A2.³³ Interference was determined by testing controls (no interfering substance added) and matched test samples (with interfering substance added). For cTnI samples ~0.50 ng/mL, the difference between the control and test samples was ≤ 10%. For cTnI samples ~0.05 ng/mL, the difference between the control and test samples was ≤ 0.006 ng/mL. For cTnI samples ~0.01 ng/mL, the control and test samples were ≤ 0.02 ng/mL. At the highest concentrations listed below, no interference was observed.

Substance	Highest Concentration Added	Substance	Highest Concentration Added
Acetaminophen	20 mg/dL	Furosemide	40 mg/dL
Acetylsalicylic Acid	65 mg/dL	Hemoglobin	5 mg/mL
Allopurinol	40 mg/dL	Human Serum Albumin	6,000 mg/dL
Ambroxol	40 mg/dL	Ibuprofen	50 mg/dL
Ampicillin	5 mg/dL	Low MW Heparin	28.8 U/mL
Ascorbic Acid	6 mg/dL	Methyldopa	2.5 mg/dL
Atenolol	1 mg/dL	Nifedipine	60 µg/mL
Bilirubin (conjugated)	40 mg/dL	Nitrofurantoin	6.4 mg/dL
Bilirubin (unconjugated)	40 mg/dL	Nystatin	2.15 mg/dL
Biotin	290 ng/mL	Oxytetracycline	24 mg/dL
Caffeine	10 mg/dL	Phenytoin	10 mg/dL
Captopril	5 mg/dL	Propranolol	500 µg/mL
Cinnarizine	40 mg/dL	Quinidine	2 mg/dL
Cocaine	2 mg/dL	Simvastatin	20 µg/mL
Diclofenac	5 mg/dL	Theophylline	25 mg/dL
Digoxin	200 ng/mL	Triglycerides	3,000 mg/dL
Dopamine	30 mg/dL	Trimethoprim	7.5 mg/dL

Substance	Highest Concentration Added		Substance	Highest Concentration Added
Erythromycin	20 mg/dL		Verapamil	16 mg/dL
Fibrinogen	1,000 mg/dL		Warfarin	30 µg/mL

To evaluate potential cross-reactivity of the assay with other myofibrillar proteins, the substances shown in the following table were added to two levels of cTnI human lithium heparin plasma samples and run on a UniCel DxI System. Values for cross-reactivity were calculated as described in CLSI EP7-A2.³³ No significant cross-reactivity was observed (< 1%).

Substance	Concentration Added (ng/mL)
Actin	1,000
Cardiac troponin C	1,000
Recombinant human CK-MB	1,000
Myoglobin	1,000
Myosin	1,000
Recombinant human cTnT	250
Skeletal troponin I	1,000
Tropomyosin	1,000

LIMIT OF BLANK

Representative data for Limit of Blank is provided for illustration only. Performance obtained in individual laboratories may vary.

The Access AccuTnI+3 assay has a Limit of Blank (LoB) of < 0.01 ng/mL (µg/L). One study determined the LoB for Access AccuTnI+3 to be 0.004 ng/mL (µg/L). LoB was tested using a protocol based on CLSI EP17-A2.²⁵

LIMIT OF DETECTION

Representative data for Limit of Detection is provided for illustration only. Performance obtained in individual laboratories may vary.


The Access AccuTnI+3 assay has a Limit of Detection (LoD) of 0.01 ng/mL (µg/L). One study determined the LoD for Access AccuTnI+3 to be 0.008 ng/mL (µg/L). LoD was tested using a protocol based on CLSI EP17-A2.²⁵

LIMIT OF QUANTITATION

Representative data for Limit of Quantitation is provided for illustration only. Performance obtained in individual laboratories may vary.

The Access AccuTnI+3 Limit of Quantitation (LoQ) is 0.04 ng/mL (µg/L) at 10% CV and 0.02 ng/mL (µg/L) at 20% CV. LoQ for Access AccuTnI+3 was determined using a protocol based on CLSI EP17-A2.²⁵ Multiple studies were completed, and a minimum of 60 replicates of several low concentration troponin I samples were measured in each study. The expected imprecision in the clinically relevant concentration range was estimated by combining data from multiple studies to create a best fit regression describing the relationship of %CV and troponin I concentration as shown in the table below.

Limit of Quantitation (imprecision estimate)



ADDITIONAL INFORMATION

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

SYMBOLS KEY

Glossary of Symbols is available at techdocs.beckmancoulter.com (document number C02724)

REFERENCES

1. Perry SV. The regulation of contractile activity in muscle. *Biochem Soc Trans* 1979; 7: 593-617.
2. Vallins WJ, Brand NJ, Dabhade N, Butler-Browne G, Yacoub MH, Barton PJ. Molecular cloning of human cardiac troponin I using polymerase chain reaction. *FEBS Lett* 1990; 270: 57-61.
3. Perry SV. Troponin I: inhibitor or facilitator. *Mol Cell Biochem* 1999; 190: 9-32.
4. Katrukha A. Antibody selection strategies in cardiac troponin assay. In: Wu AHB, editor. *Cardiac markers*, 2nd ed. Totowa (NJ): Humana Press Inc., 2003, 173-185.
5. Larue C, Defacque-Lacquement H, Calzolari C, Le Nguyen D, Pau B. New monoclonal antibodies as probes for human cardiac troponin I: epitopic analysis with synthetic peptides. *Mol Immunol* 1992; 29: 271-278.
6. Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Puschendorf B. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. *Clin Chem* 1995; 41: 1266-1272.
7. Mair J, Genser N, Morandell D, Maier J, Mair P, Lechleitner P, Calzolari C, Larue C, Ambach E, Dienstl F, Pau B, Puschendorf B. Cardiac troponin I in the diagnosis of myocardial injury and infarction. *Clin Chim Acta*. 1996; 245: 19-38.
8. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. *J Am Coll Cardiol* 2006; 48: 1-11.
9. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. *CMAJ* 2005; 173: 1191-1202.
10. Jeremias A, Gibson CM. Narrative Review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. *Ann Intern Med* 2005; 142: 786-91.
11. Thygesen K, Alpert JS, White HD; Joint ESC/ACC/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J* 2007; 28: 2525-38. *J Am Coll Cardiol* 2007; 50: 2173-95. *Circulation* 2007; 116: 2634-53.
12. Thygesen K, Alpert JS, Jaffe AS. Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. *Eur Heart J* 2012; 33: 2551-67. *J Am Coll Cardiol* 2012; 60: 1581-98. *Circulation* 2012; 126: 2020-35. Available online at: www.escardio.org/guidelines.
13. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Eur Heart J* 2000; 21: 1502-1513. *J Am Coll Cardiol* 2000; 36: 959-969.
14. Hamm CW, Giannitsis E, Katus HA. Cardiac troponin elevations in patients without acute coronary syndrome. *Circulation* 2002; 106: 2871-2872.
15. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery disease. *Clin Chem* 1999; 45: 1104-1121.
16. Approved Guideline - Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests, GP44-A4. 2010. Clinical and Laboratory Standards Institute.
17. Troponin: what laboratorians should know to manage elevated results. <http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/TipsandArticlesonDeviceSafety/ucm109362.htm>

18. Approved Standard - Sixth Edition, Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture, H3-A6. 2007. Clinical and Laboratory Standards Institute.
19. Cembrowski GS, Carey RN. Laboratory quality management: QC = QA. ASCP Press, Chicago, IL, 1989.
20. Fesmire FM, Decker WW, Diercks DB, Ghaemmaghami CA, Nazarian D, Brady WJ, Hahn S, Jagoda AS; American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Non-ST-Segment Elevation Acute Coronary Syndromes. Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. *Ann Emerg Med.* 2006; 48: 270-301.
21. Approved Guideline - Clinical Evaluation of Immunoassays, I/LA 21-A2, 2008. Clinical and Laboratory Standards Institute.
22. Jaffe AS, Apple FS; High Sensitivity Cardiac Troponin: Hype, Help, and Reality. *Clin Chem* 2010; 56:342-344.
23. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs non-coronary disease. *Eur Heart J.* 2011; 32: 404-411.
24. Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. *Clin Chem* 2009; 55: 2098-2122.
25. Approved Guideline - Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, EP17-A2. June 2012. Clinical and Laboratory Standards Institute.
26. Kricka L. Interferences in immunoassays - still a threat. *Clin Chem* 2000; 46: 1037-1038.
27. Bjerner J, Nustad K, Norum LF, Olsen KH, Børmer OP. Immunometric assay interference: incidence and prevention. *Clin Chem* 2002; 48: 613-621.
28. Lum G, Solarz D, Farney L. False Positive Cardiac Troponin Results in Patients Without Acute Myocardial Infarction. *Labmedicine* 2006; 37(9): 546-550.
29. Lingwood D, Ballantyne JS. Alkaline phosphatase-immunoglobulin conjugate binds to lipids in vitro, independent of antibody selectivity. *J Immunol Methods* 2006; 311: 174-177.
30. Mitchell JRA. Back to the future: so what will fibrinolytic therapy offer your patients with myocardial infarction? *Br Med J* 1986; 292: 973-978.
31. Approved Guideline - Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach, EP06-A. April 2003. Clinical and Laboratory Standards Institute.
32. Approved Guideline - Evaluation of Precision Performance of Quantitative Measurement Methods, EP5-A2. August 2004. Clinical and Laboratory Standards Institute.
33. Approved Guideline - Interference Testing in Clinical Chemistry, EP7-A2. November 2005. Clinical and Laboratory Standards Institute.

EC REP Beckman Coulter Eurocenter S.A., 22, rue Juste-Olivier. Case Postale 1044, CH - 1260 Nyon 1, Switzerland
Tel: +41 (0)22 365 36 11

 Beckman Coulter, Inc., 250 S. Kraemer Blvd., Brea, CA 92821 U.S.A.